Shots:

• Biocon Biologics will perform all end-to-end development activities- IND filing- manufacturing and commercialization post-regulatory approval in its own authorized global markets for assets and will utilize Just - Evotec Biologics’ expertise in process development domain mainly in optimized manufacturability
• Just - Evotec Biologics to receive license fee plus development- regulatory and commercial milestone payments. The focus of the agreement is to expand Biocon Biologics’ biosimilar portfolio with the addition of Just - Evotec’s pre-clinical candidates and utilizing their late-stage development- manufacturing and commercial capabilities plus technology for further development
• Biocon Biologics has pipeline of 28 candidates including 11 with Mylan some with Sandoz and focusses to develop therapies in diabetes- oncology- immunology- dermatology- ophthalmology- neurology- rheumatology and inflammatory diseases

Click here to­ read full press release/ article | Ref: Evotec | Image: Twitter